Markova, J., Kobe, C., Skopalova, M., Klaskova, K., Dedeckova, K., Plütschow, A., ...
Background: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of...
© 1999 Khmer Academic Publishers. Printed in the Netherlands. (2008)
U. Rueffer, M. Sieber, A. Josting, K. Breuer, F. J. Grotenhermen, H. Bredenfeld, ...
Prognostic factors for subdiaphragmatic involvement in clinical stage I—II supradiaphragmatic Hodgkin's disease: A retrospective analysis of the GHSG
Hagenbeek, A., Gadeberg, O., Johnson, P., Pedersen, L.M., Walewski, J., Hellmann, A., ...
Ofatumumab is a unique monoclonal antibody that targets a distinct small loop epitope on the CD20 molecule. Preclinical data show that ofatumumab is active against B-cell lymphoma/chronic lymphocytic...
Sieniawski, M., Reineke, T., Josting, A., Nogova, L., Behringer, K., Halbsguth, T., ...
Background: Infertility is one of the most significant side-effects in long-term survivors of successfully treated Hodgkin's lymphoma (HL). Patients and methods: The fertility status was assessed in...
Klimm, B, Eich, HT, Haverkamp, H, Lohri, A, Koch, P, Boissevain, F, ...
Background: The optimal treatment of elderly patients with Hodgkin's lymphoma (HL) is still a matter of debate. Since many of these patients receive combined modality treatment, we evaluated the...
Klimm, B., Eich, H. T., Haverkamp, H., Lohri, A., Koch, P., Boissevain, F., ...
Background: The optimal treatment of elderly patients with Hodgkin's lymphoma (HL) is still a matter of debate. Since many of these patients receive combined modality treatment, we evaluated the...
Klimm, B., Eich, H. T., Haverkamp, H., Lohri, A., Koch, P., Boissevain, F., ...
Background: The optimal treatment of elderly patients with Hodgkin's lymphoma (HL) is still a matter of debate. Since many of these patients receive combined modality treatment, we evaluated the...
Josting, A., Sieniawski, M., Staak, O., Nogova, L., Peters, N., ...
Background: Combination chemotherapy can cure patients with non-Hodgkin's lymphoma (NHL), but those who suffer treatment failure or relapse still have a poor prognosis. High-dose chemotherapy (HDCT)...
Josting, A., Rudolph, C., Mapara, M., Sienawski, M., Sieber, M., ...
Background: We designed a dose- and time-intensified high-dose sequential chemotherapy regimen for patients with relapsed and refractory Hodgkin lymphoma (HD). Patients and methods: Eligibility...
Ballova, V., Haverkamp, H., Pfistner, B., Müller-Hermelink, H. K., Dühmke, E., ...
In contrast to younger patients, the prognosis of elderly patients with advanced Hodgkin's disease (HD) has not improved substantially over the last 20 years. We thus carried out a prospectively...
Recombinant human erythropoietin in oncology: current status and further developments (2005)
Anaemia effects up to 90% of cancer patients, with more than 60% requiring blood transfusion during or after treatment. With the advent of recombinant human erythropoietins (rHuEPO), an alternative...
Nogová, L., Reineke, T., Eich, H. T., Josting, A., Müller-Hermelink, H. K., Wingbermühle, K., ...
Background: Since there are no randomized studies, the treatment of choice for patients with early stage lymphocyte-predominant Hodgkin's lymphoma (LPHL) remains unclear. We thus reviewed all LPHL...
Josting, A., Sieniawski, M., Staak, O., Nogova, L., Peters, N., ...
Background: Combination chemotherapy can cure patients with non-Hodgkin's lymphoma (NHL), but those who suffer treatment failure or relapse still have a poor prognosis. High-dose chemotherapy (HDCT)...
Recombinant human erythropoietin in oncology: current status and further developments (2005)
Anaemia effects up to 90% of cancer patients, with more than 60% requiring blood transfusion during or after treatment. With the advent of recombinant human erythropoietins (rHuEPO), an alternative...
Nogová, L., Reineke, T., Eich, H. T., Josting, A., Müller-Hermelink, H. K., Wingbermühle, K., ...
Background: Since there are no randomized studies, the treatment of choice for patients with early stage lymphocyte-predominant Hodgkin's lymphoma (LPHL) remains unclear. We thus reviewed all LPHL...
Rothe, A., Klimka, A., Tur, M.K., Pfitzner, T., Huhn, M., Sasse, S., ...
The display of recombinant antibody fragments on the surface of filamentous phage mimicks B cells and is therefore a technology ideal to generate antibodies against any potential target antigen in...
Sieber, M., Tesch, H., Pfistner, B., Rueffer, U., Paulus, U., Munker, R., ...
Background: The purpose of this study was to compare the efficacy of the hybrid chemotherapeutic regimen COPP/ABV/IMEP...
Behringer, K., Josting, A., Schiller, P., Eich, H. T., Bredenfeld, H., Diehl, V., ...
Background: Long-term survivors of successfully treated Hodgkin's disease (HD) are at risk for late complications. Among these, secondary solid tumors are most serious because they are often fatal....
Tur, M.K., Rothe, A., Huhn, M., Goerres, U., Klimka, A., Stocker, M., ...
Isolation of cell-surface specific antibodies prerequisites the functional expressing of antigens on intact cells, which are maintained routinely by cell culturing. However, long-term culturing of...
Stöcker, M., Tur, M.K., Sasse, S., Krüßmann, A., Barth, S., Engert, A.
Immunotoxins consist of a target-cell-specific binding moiety, chemically or recombinantly linked to a cytotoxic component. A number of different immunotoxins (IT) have increasingly been evaluated...
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab (2003)
Boye, J., Elter, T., Engert, A.
The chimeric anti-CD20 monoclonal antibody rituximab has become part of the standard therapy for patients with non-Hodgkin’s lymphoma (NHL). To date, more than 300 000 patients have been treated...
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma (2003)
Schnell, R., Borchmann, P., Staak, J. O., Schindler, J., Ghetie, V., Vitetta, E. S., ...
Background: Immunotoxins (ITs) consist of cell binding ligands coupled to toxins or their subunits. Hodgkin’s lymphoma (HL) is an excellent target for ITs since lymphocyte activation markers such...
Adili, F., Scholz, T., Hille, M., Heckenkamp, J., Barth, S., Engert, A., ...
Objective: accelerated re-endothelialisation may inhibit the development of restenosis. Basic Fibroblast Growth Factor (bFGF) plays a key role for early proliferative activity in the artery following...
Pfister, K., Wittig, B.M., Jüngling, B., Ecker, K.W., Barth, S., Huhn, M., ...
Background and aims: In chronic inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis an aberrant mucosal immune regulation is observed accompanied by upregulation of...
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia (2002)
Pfitzner, T., Reiser, M., Barth, S., Borchmann, P., Schulz, H., Schinköthe, T., ...
New therapeutic approaches for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) can induce remarkable responses. Molecular remissions have been observed occasionally after high-dose...
Current strategies of antibody-based treatment in Hodgkin's disease (2002)
Schnell, R., Borchmann, P., Schulz, H., Engert, A.
Many new approaches involving antibody‐based agents have given promising results in experimental Hodgkin's disease (HD) models. Clinical trials with monoclonal antibodies, immunotoxins,...
Josting, A., Rudolph, C., Reiser, M., Mapara, M., Sieber, M., Kirchner, H. H., ...
Background: An important variable affecting outcome in relapsed and refractory Hodgkin’s disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume before high-dose...
Tur, M.K., Sasse, S., Stöcker, M., Djabelkhir, K., Huhn, M., Matthey, B., ...
Since the disialoganglioside GD2 is abundantly present on the surface of neuroblastoma cells, we constructed a new recombinant immunotoxin for possible clinical use in patients with neuroblastoma. A...
Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells (2001)
Sundarapandiyan, K., Keler, T., Behnke, D., Engert, A., Barth, S., Matthey, B., ...
Huhn, M., Sasse, S., Tur, M.K., Matthey, B., Schinköthe, T., Rybak, S., ...
A number of different immunotoxins composed of cell-specific targeting structures coupled to plant or bacterial toxins have increasingly been evaluated for immunotherapy. Because these foreign...
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment (2001)
Rueffer, U., Breuer, K., Josting, A., Lathan, B., Sieber, M., Manzke, O., ...
Infertility after treatment of patients with Hodgkin's disease (HD) is considered as a side effect of alkylating agent containing chemotherapy regimens To investigate whether gonadal failure is...
Borchmann, P., Schnell, R., Knippertz, R., Staak, J. O., Camboni, G. M., Bernareggi, A., ...
Background: BBR 2778 is a novel aza-anthracenedione showing no cardiotoxicity and superior activity compared to doxorubicin and mitoxantrone in animal models. Objectives of this phase I study...
Barth, S., Huhn, M., Matthey, B., Tawadros, S., Schnell, R., Diehl, V., ...
Sieber, M., Engert, A., Diehl, V.
Background: Treatment strategies in Hodgkin's disease (HD) are changing fundamentally over the last decades. Both radiotherapy and combination chemotherapy are effective treatment modalities....
Rueffer, U., Sieber, M., Josting, A., Breuer, K., Grotenhermen, F. J., Bredenfeld, H., ...
Background: Staging laparotomy and splenectomy were routinely performed in patients with early-stage Hodgkin's disease (HD) qualifying for radiotherapy alone to determine the exact extent of disease....
New drugs in the treatment of Hodgkin's disease (1998)
Borchmann, P., Schnell, R., Diehl, V., Engert, A.
In the treatment of Hodgkin's disease (HD) remission rates of 80% have been achieved with combination regimens such as COPP/ABVD; 30%–50% of these patients relapse, however, and less than 25% of...
BEACOPP: A new regimen for advanced Hodgkin's disease (1998)
Diehl, V., Franklin, J., Hasenclever, D., Tesch, H., Pfreundschuh, M., Lathan, B., ...
The BEACOPP chemotherapy regimen for advanced Hodgkin's disease employs a rearranged schedule permitting a shortened three-week cycle. With haematological growth factor support, the dosages of...
Wolf, J., Tesch, H., Parsa-Parsi, R., Engert, A., Diehl, V.
Strategies in the treatment of adult Hodgkin's disease (HD) are changing strikingly in current clinical trials. In early as well as in intermediate stage HD a common aim of most study groups now is...
Josting, A., Kátay, I., Rueffer, U., Winter, S., Tesch, H., Engert, A., ...
Background: Disease status before high-dose chemotherapy with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBSCT) is an important predictor of...
The emerging role of immunotoxins in leukemia and lymphoma (1997)
Winkler, U., Barth, S., Schnell, R., Diehl, V., Engert, A.
Despite important advances in conventional cancer therapy, there is still a strong need for new approaches in order to reduce cancer death rates, which have not been drastically influenced in the...
Development of immunotoxins for potential clinical use in Hodgkin's disease (1996)
Barth, S., Schnell, R., Diehi, V., Engert, A.
During the last decade, immunotoxins (ITs) consisting of a cell-binding moiety and a potent toxin were developed as a new class of biological anti-tumor agents. Hodgkin's disease has shown to be one...
Current clinical trials in Hodgkin's disease (1996)
Reuß, K., Engert, A., Tesch, H., Diehi, V.
With the advent of modern polychemotherapy and radiation techniques, cure rates in Hodgkin's disease (HD) have improved substantially. This article summarises current concepts of treatment for early,...
Engelhard, M., Gerhartz, H., Brittinger, G., Engert, A., Fuchs, R., Geiseler, B., ...
In high-grade malignant non-Hodgkin's lymphomas (hNHL) recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was evaluated as support to chemotherapy. In a phase III trial,...
Kapp, U., Düx, A., Schell-Frederick, E., Banik, N., Hummel, M., Mücke, S., ...
Local tumor growth has been reported after subcutaneous and intraperitoneal injection of Hodgkin's disease (HD) derived cell lines into different immunodeficient mouse strains. An animal model with...
Immunotoxins:Is there a clinical value? (1994)
Gottstein, C., Winkler, U., Bohlen, H., Diehl, V., Engert, A.
Drug targeting is an attractive new approach to killing malignant cells, thereby leaving normal tissue unharmed. A decisive breakthrough was the advent of hybridoma technology, making monoclonal...
Strohscheer, I., Kleinert, R., Westphal, C., Schüller, J., Werner, K., Anders, O., ...
Peer Reviewed
Preliminary report: Growth of Hodgkin's lymphoma derived cells in immune compromised mice (1992)
Kapp, U., Wolf, J., Von Kalle, C., Tawadros, S., Röttgen, A., Engert, A., ...
Until now there has been no satisfactory animal host for the in vivo growth of Hodgkin lymphoma cells. With the exception of one mutant subline (L540Cy) none of the other Hodgkin derived cell lines...
Experimental therapy in Hodgkin's disease (1992)
Engert, A., Pohl, C., Diehl, V.
Hodgkin/Reed-Sternberg (H-RS) cells express lymphoid activation markers like CD25 and CD30 which are present only on a small minority of normal cells. Currently, most experimental approaches in...
Barth, S., Huhn, M., Matthey, B., Klimka, A., Galinski, E. A., Engert, A.
The standard method of producing recombinant proteins such as immunotoxins (rITs) in large quantities is to transform gram-negative bacteria and subsequently recover the desired protein from...
Barth, S., Huhn, M., Matthey, B., Klimka, A., Galinski, E. A., Engert, A.
The standard method of producing recombinant proteins such as immunotoxins (rITs) in large quantities is to transform gram-negative bacteria and subsequently recover the desired protein from...
CASTELLETTI, D, FRACASSO, G, RIGHETTI, S, TRIDENTE, G, SCHNELL, R, ENGERT, A, ...
Hodgkin's lymphoma patients treated with an anti-CD25 Ricin toxin A-chain (RTA)-based Immunotoxin (RFT5.dgA) develop an immune response against the toxic moiety of the immunoconjugate. The anti-RTA...
Klimka, A, Barth, S, Matthey, B, Roovers, R C, Lemke, H, Hansen, H, ...
Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning
Klimka, A, Matthey, B, Roovers, R C, Barth, S, Arends, J-W, Engert, A, ...
In various clinical studies, Hodgkin’s patients have been treated with anti-CD30 immunotherapeutic agents and have shown promising responses. One of the problems that appeared from these studies is...